News

The glatiramer acetate depot formulation is to be injected once-a-month under the skin or into a muscle for a prolonged release of the therapeutic agent. Mapi Pharma president

Alimera Sciences, pSivida’s licensee, has reported the treatment of first patient following the commercial launch in the region. pSivida president and chief executive officer Dr. Paul Ashton said

Sativex is indicated for the treatment of moderate to severe spasticity in multiple sclerosis (MS) in patients who showed inadequate response to other anti-spasticity medications. GW chief executive

Net sales for the first quarter ended 31 March 2013 were Rs6.32bn ($117.13m) compared to Rs6.23bn ($115.46m) for the first quarter ended 31 March 2012. GlaxoSmithKline Pharmaceuticals managing

The company expects to convert manufacturing capacity at the facility to allow future production of the once-weekly GLP-1 analogue type 2 diabetes therapy. Operations at the converted plant

As per the agreement, Astellas’ ASP7035, which completed a phase I study and is yet to enter into phase IIa-study, will be licensed to Tacurion. Tacurion will be

ALX-0962 comprises anti-IgE Nanobody with dual mode of action and a serum albumin binding Nanobody for in vivo plasma half-life extension. Ablynx chairman and CEO Dr Edwin Moses

The partnership will enable CML to increase its market share in the specialized CRO custom bioanalytical testing space, currently serviced by its subsidiary, Hemostasis Reference Laboratory. Expected to

In February 2013, the Agency had granted Fast Track status for ceftolozane/tazobactam in Complicated Intra-Abdominal Infections (cIAI). Cubist Pharmaceuticals Chief Scientific Officer Steven Gilman said that the incentive,